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Introduction {#sec001}
============

In Taiwan and worldwide, lung cancer is the leading cause of cancer-related mortality \[[@pone.0178676.ref001]\]. About half of lung cancers are found at the advanced stage at diagnosis \[[@pone.0178676.ref002]\]. According to the lung cancer staging system of the American Joint Committee on Cancer (AJCC), 7th edition, lung to lung metastasis, pleural metastasis, and distant metastasis such as to brain, bone, and liver, among others, are classified as M1 disease and represent terminal stage cancer \[[@pone.0178676.ref003]\]. Median survival in patients with advanced lung cancer is usually 1 year or less \[[@pone.0178676.ref004]\], and patients with epidermal growth factor receptor *(EGFR)-*mutant metastatic non-small-cell lung cancer (NSCLC) may have longer overall survival (OS) when treated with tyrosine kinase inhibitors (TKIs) \[[@pone.0178676.ref005],[@pone.0178676.ref006]\]. In the prediction of lung cancer survival, well-accepted prognostic factors are disease extent and Eastern Cooperative Oncology Group (ECOG) performance status (PS) \[[@pone.0178676.ref004]\]. Other predictors of survival such as extremes of age, carcinoembryonic antigen, *EGFR* mutation status, lymphocyte-to-monocyte ratio (LMR), number of metastatic sites, and hypoalbuminemia have also been proposed \[[@pone.0178676.ref004],[@pone.0178676.ref007]--[@pone.0178676.ref013]\]. Therefore, even for cancers in the same stage, prognosis may be different. In castration-resistant prostate cancer, one study showed that patients with liver metastasis have shorter median OS \[[@pone.0178676.ref014]\]. Moreover, resection of liver metastasis in colorectal cancer was found to improve outcomes \[[@pone.0178676.ref015]\]. Thus, liver metastasis seem to play a role in the prognosis of both prostate cancer and colon cancer. However, no previous studies have examined their role in lung cancer outcomes. Therefore, we conducted a retrospective analysis to investigate the impact of liver metastasis on outcome in stage IV NSCLC patients. We also aimed to examine whether positive EGFR mutation status and first-line treatment with EGFR-TKIs reversed poor prognosis in stage IV NSCLC patients with *de novo* liver metastasis (DLM).

Materials and methods {#sec002}
=====================

We retrospectively reviewed medical records of patients diagnosed with advanced NSCLC from November 2010 to March 2014 at Kaohsiung Chang Gung Memorial Hospital. Patients were included if they were over 18 years old and had confirmed stage IV NSCLC according to the AJCC 7^th^ edition criteria \[[@pone.0178676.ref003]\]. Lung cancer staging included chest computed tomography (CT); brain imaging (CT or magnetic resonance imaging); bone scans; pleural effusion cytology; and, in some cases, positron emission tomography. Data including basic information, metastatic site, progression-free survival (PFS), OS, and other related factors were collected and analyzed. PFS was defined as the period from the first day of treatment to documented disease progression, or death prior to disease progression. OS was defined as the period from the first day of treatment to death. Disease progression was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 \[[@pone.0178676.ref016]\]. PS was defined based on ECOG criteria \[[@pone.0178676.ref017]\]. EGFR mutation analysis was performed using the Scorpion and amplified refractory mutation system (ARMS) techniques with formalin-fixed and paraffin-embedded tissue. DLM was defined as liver metastasis confirmed at the time of initial diagnosis.

Statistical analyses were performed using MedCalc (version14.10.2). PFS and OS were analyzed using Kaplan-Meier curves and log-rank testing. We used Cox proportional hazards regression models to evaluate independent factors that affected survival outcomes. Youden\'s index and receiver operating characteristic (ROC) curves were used to determine the best cutoff value of LMR. Comparisons of baseline clinical parameters between NSCLC patients with or without liver metastasis were made using the chi-square test or Fisher's exact test for categorical variables and the unpaired t-test or Wilcoxon rank-sum test for continuous variables as appropriate. A p value \< 0.05 was considered statistically significant.

The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, and the requirements for patient consent were waived (IRB:103-3226B).

Results {#sec003}
=======

Patient and clinical characteristics {#sec004}
------------------------------------

A total of 1510 patients received new diagnoses of lung cancer, and 1392 of these patients were diagnosed with NSCLC. Among these NSCLC patients, 490 patients with stage IV disease were included for evaluation, as shown in [Fig 1](#pone.0178676.g001){ref-type="fig"}. All EGFR-mutant patients received first-line treatment with TKIs, and patients with wild-type EGFR tumors received first-line chemotherapy or conservative treatment in cases of poor PS, according to clinician judgment. Mean age of all 490 patients was 63.8 ± 12.4 years. Basic data and clinical parameters are shown in [Table 1](#pone.0178676.t001){ref-type="table"}.

![Inclusion and patient selection.](pone.0178676.g001){#pone.0178676.g001}
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###### Comparison of baseline clinical parameters between NSCLC patients with or without liver metastasis.

![](pone.0178676.t001){#pone.0178676.t001g}

  -------------------------------------------------------------------------------------------------------------
                           With *de novo* liver metastasis\   Without *de novo* liver metastasis\   *P* value
                           (n = 75)                           (n = 415)                             
  ------------------------ ---------------------------------- ------------------------------------- -----------
  Age, years               61.8 ± 12.4                        64.2 ± 12.3                           0.130

  BMI                      22.5 ± 3.5                         22.9 ± 3.9                            0.428

  Sex                                                                                               0.062

      Male                 29 (38.7)                          209 (50.4)                            

      Female               46 (61.3)                          206 (49.6)                            

  DM                                                                                                0.835

      Yes                  8 (10.7)                           41 (9.9)                              

      No                   67 (89.3)                          374 (90.1)                            

  Smoking history                                                                                   0.082

      Never                54 (72.0)                          255 (61.4)                            

      Former / current     21 (28.0)                          160 (38.6)                            

  Performance status                                                                                0.443

      ECOG 0--2            66 (88.0)                          377 (90.8)                            

      ECOG 3--4            9 (12.0)                           38 (9.2)                              

  EGFR mutation                                                                                     0.435

      Yes                  39 (52.0)                          236 (56.9)                            

      No                   36 (48.0)                          179 (43.1)                            

  Tumor type                                                                                        0.758

      Adenocarcinoma       65 (86.7)                          354 (85.3)                            

      Non-adenocarcinoma   10 (13.3)                          61 (14.7)                             

  LMR \> 3.1               30 (40)                            231 (55.7)                            0.002

  Brain metastasis         25 (33.3)                          99 (23.9)                             0.083

  Bone metastasis          48 (64.0)                          197 (47.5)                            0.008

  Pleural metastasis       22 (29.3)                          179 (47.5)                            0.025
  -------------------------------------------------------------------------------------------------------------

BMI, body-mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; NSCLC, non-small-cell lung cancer.

Among the study patients, 75 patients had DLM, while 415 patients did not. There were no significant differences between these two groups in age, body mass index, sex distribution, presence of diabetes mellitus, smoking history, ECOG PS, EGFR mutation status, tumor type, or presence of brain metastasis. There were significantly fewer instances of LMR \> 3.1, fewer cases of pleural metastasis, and more cases of bone metastasis in the DLM group. The best cutoff point for LMR determined by ROC curves was 3.1.

Further univariate and multivariate analysis of 490 NSCLC patients are shown in [Table 2](#pone.0178676.t002){ref-type="table"}. BMI, sex, DM, ECOG PS, EGFR mutant status, tumor type, LMR, DLM were predictive factors in univariate analysis. Multivariate analysis showed that male gender, EOCG PS 3--4, without EGFR mutation, LMR ≤ 3.1, DLM were negative predictors for OS.

10.1371/journal.pone.0178676.t002

###### Impact of baseline clinical parameters on NSCLC patients.

![](pone.0178676.t002){#pone.0178676.t002g}

                       Univariate analysis   Multivariate analysis                                      
  -------------------- --------------------- ----------------------- ------ --------- ------- --------- --------------
  Age, years                                                                                            
      \>60             295                   238                     12.0   0.136                       
      ≤ 60             195                   154                     14.4                               
  BMI                                                                                                   
      \>22             278                   214                     14.4   0.002     0.811   0.051     0.657--1.001
      ≤ 22             212                   178                     11.1                               
  Sex                                                                                                   
      Male             238                   197                     11.9   0.005             0.012     0.618--0.943
      Female           252                   195                     15.3             0.764             
  DM                                                                                                    
      Yes              49                    46                      9.3    0.015     1.172   0.332     0.851--1.613
      No               441                   346                     13.4                               
  Smoking history                                                                                       
      Never            309                   244                     14.0   0.072                       
      Former/current   181                   148                     11.1                               
  Performance status                                                                                    
  ECOG 0--2            442                   349                     13.6   \<0.001           0.001     1.281--2.520
  ECOG 3--4            48                    43                      3.7              1.797             
  EGFR mutation                                                                                         
      Yes              275                   198                     18.6   \<0.001   0.569   \<0.001   0.458--0.708
      No               215                   194                     7.5                                
  Tumor type                                                                                            
      ADC              419                   327                     13.4   0.009             0.840     0.780--1.358
      Non-ADC          71                    65                      10.2             1.029             
  LMR                                                                                                   
      \>3.1            260                   193                     18.4   \<0.001           \<0.001   1.212--1.837
      ≤3.1             208                   191                     7.7              1.844             
  DLM                                                                                                   
  Yes                  415                   324                     13.6   \<0.001           0.01      1.092--1.880
  No                   75                    68                      8.8              1.432             

ADC, adenocarcinoma; BMI, body mass index; DM, diabetes mellitus; DLM, *de novo* liver metastases; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; mo, months; NSCLC, non-small-cell lung cancer; OS, overall survival.

Clinical characteristics of NSCLC patients with *de novo* liver metastasis {#sec005}
--------------------------------------------------------------------------

The results of univariate and multivariate analysis in the DLM group are shown in [Table 3](#pone.0178676.t003){ref-type="table"}. ECOG PS 3--4 and LMR ≦ 3.1 were found to be associated with poor outcome, with hazard ratios of 1.5 and 7.4, respectively, in univariate analysis. Further analysis of these two parameters in multivariate analysis revealed hazard ratios of 6.83 (ECOG PS 3--4) and 2.10 (LMR ≦ 3.1). Extrahepatic metastasis were not found to affect outcome in univariate analysis in the DLM group.

10.1371/journal.pone.0178676.t003

###### Impact of baseline clinical parameters on NSCLC patients with *de novo* liver metastasis.
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                            Univariate analysis   Multivariate analysis                                   
  ------------------------- --------------------- ----------------------- ------ ------- ------ --------- ---------------
  Age, years                                                                                              
      \>60                  34                    30                      8.8    0.555                    
      ≤ 60                  41                    38                      8.8                             
  BMI                                                                                                     
      \>22                  41                    36                      11.4   0.166                    
      ≤ 22                  34                    32                      7.4                             
  Sex                                                                                                     
      Male                  29                    27                      8.3    0.901                    
      Female                46                    41                      9.0                             
  DM                                                                                                      
      Yes                   8                     8                       9.5    0.899                    
      No                    67                    60                      8.8                             
  Smoking history                                                                                         
      Never                 54                    49                      9.0    0.781                    
      Former/current        21                    19                      6.9                             
  Performance status                                                                                      
  ECOG 0--2                 66                    59                      9.5    0.001          \<0.001   2.478--18.802
  ECOG 3--4                 9                     9                       1.5            6.83             
  EGFR mutation                                                                                           
      Yes                   39                    35                      11.9   0.155                    
      No                    36                    33                      7.7                             
  Tumor type                                                                                              
      ADC                   65                    58                      8.7    0.325                    
      Non-ADC               10                    10                      8.8                             
  LMR                                                                                                     
  \>3.1                     29                    24                      12.8   0.036          0.033     1.061--4.166
  ≤3.1                      45                    43                      7.4            2.10             
  Extrahepatic metastasis                                                                                 
  Yes                       69                    62                      8.7    0.417                    
  No                        6                     6                       17.1                            

ADC, adenocarcinoma; BMI, body mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; mo, months; NSCLC, non-small-cell lung cancer; OS, overall survival.

Impact of EGFR mutation status on patients with *de novo* liver metastasis {#sec006}
--------------------------------------------------------------------------

Among patients with DLM, those who had EGFR mutation-positive disease and received EGFR-TKIs as first-line therapy had longer PFS than those with EGFR wild-type tumors (EGFR mutant vs. wild-type: PFS: 5.9 vs. 3.5 months, p = 0.046) (Figs [2](#pone.0178676.g002){ref-type="fig"} and [3](#pone.0178676.g003){ref-type="fig"}). However, in patients with DLM, no significant OS benefit was observed in EGFR-mutant patients compared to those with EGFR wild-type disease in univariate analysis (EGFR mutant vs. wild-type: OS: 11.9 vs. 7.7 months, p = 0.155).

![Progression-free survival regarding *de novo* liver metastasis and epidermal growth factor receptor mutation status.](pone.0178676.g002){#pone.0178676.g002}

![Overall survival regarding *de novo* liver metastasis and epidermal growth factor receptor mutation status.](pone.0178676.g003){#pone.0178676.g003}

Impact of EGFR mutation status on patients without *de novo* liver metastasis {#sec007}
-----------------------------------------------------------------------------

In patients without DLM, those who had EGFR mutation-positive disease and received EGFR-TKIs as first-line therapy had longer PFS than those with EGFR wild-type tumors (EGFR mutant vs. wild type: PFS: 10.6 vs. 3.4 months, p \< 0.001) (Figs [2](#pone.0178676.g002){ref-type="fig"} and [3](#pone.0178676.g003){ref-type="fig"}). Furthermore, in patients without DLM, OS was longer in EGFR-mutant patients than in those with EGFR wild-type disease (EGFR mutant vs. wild-type: OS: 20.2 vs. 7.3 months, p \< 0.001).

Impact of DLM status on patients with EGFR-mutant and wild-type NSCLC {#sec008}
---------------------------------------------------------------------

In patients with EGFR-mutant NSCLC, those with DLM had worse PFS and OS than those without DLM (DLM vs. non-DLM: PFS: 5.9 vs. 10.6 months, p \< 0.001; OS: 11.9 vs. 20.2 months, p \< 0.001). For those with EGFR wild-type NSCLC, the prognosis of non-DLM patients was no better than that of DLM patients (DLM vs. non-DLM: PFS: 3.5 vs. 3.4 months, p = 0.634; OS: 7.7 vs. 7.3 months, p = 0.521). It can be seen that the occurrence of DLM in patients with EGFR-mutant NSCLC results in outcomes as poor as those in patients with EGFR wild-type disease, with or without DLM.

Discussion {#sec009}
==========

The liver is a less common metastatic site of NSCLC than brain and bone, with an incidence of 47/72 (brain), 36/72 (bone), and 22/72 (liver) observed in the study by Quint et al \[[@pone.0178676.ref018],[@pone.0178676.ref019]\]. Specific factors affecting metastasis to each particular site remain poorly understood. Hsu et al. found that among NSCLC patients, those with younger age and EGFR-mutant disease have a higher incidence of brain metastasis at initial diagnosis \[[@pone.0178676.ref020]\]. However, the authors did not present data regarding other concurrent metastatic sites. Chen et al. found that patients younger than 40 years of age were more likely to have brain, bone, liver, and pleural metastasis \[[@pone.0178676.ref021]\]. Furthermore, NSCLC patients with *ALK* gene rearrangement and EGFR mutations are more likely to have liver metastasis compared to patients without *ALK* gene rearrangement, EGFR mutation, and *KRAS* mutation \[[@pone.0178676.ref022]\]. Thus, EGFR mutation status and age appear to have some influence on brain or liver metastasis. However, in our study, age and prevalence of EGFR-mutant disease did not differ between the DLM and non-DLM groups. Furthermore, we observed an increased frequency of bone and pleural metastasis in the DLM group. In a study of 1074 patients with non-metastatic NSCLC treated with radiation therapy, the four most frequent sites of initial distant metastasis were brain (146/456), lung/effusion (125/456), bone (98/456), and liver (63/456) \[[@pone.0178676.ref023]\]. Thus, brain and bone seem more likely first sites of distant metastasis than liver. Accordingly, if a patient has liver metastasis, other concurrent distant metastasis may exist. This could partially explain our finding of a greater frequency of bone and pleural metastasis in the DLM group. The presence of liver metastasis may suggest more terminal status in stage IV NSCLC, since patients with liver metastasis tend to also have additional distant metastasis, and a greater number of metastatic sites predicts worse survival \[[@pone.0178676.ref004],[@pone.0178676.ref008]\]. This could help explain why in our study, DLM patients were found to have worse prognosis than those in the non-DLM group. However, this question will require further study for confirmation.

In the current study, the presence of EGFR mutations and first-line treatment with EGFR-TKIs were found to improve both PFS and OS in patients without DLM, as well as improve PFS in patients with DLM, but were associated with no improvement in OS in patients with DLM. A previous study by Vikram et al. showed that in stage IV NSCLC, brain, bone, and liver metastasis were not predictors of survival \[[@pone.0178676.ref008]\]. However, in the study by Hoang et al., liver metastasis was identified as a poor prognostic factor in patients with stage IIIB or IV NSCLC \[[@pone.0178676.ref004]\]. Furthermore, liver or bone metastasis as the first site of distant metastasis after radiation therapy for NSCLC was found to be associated with worse prognosis \[[@pone.0178676.ref023]\]. The results of these studies were not consistent, and the studies were performed in the era prior to EGFR mutation testing and TKIs. It has been demonstrated that TKIs improved PFS in EGFR-mutant NSCLC \[[@pone.0178676.ref024]\], and were also able to prolong OS \[[@pone.0178676.ref025]\]. The present study revealed that TKIs could improve both PFS and OS in patients without DLM, but in patients with DLM, administration of TKIs could not prolong OS even in cases of EGFR-mutant disease. A recent study conducted by Wu et al. showed that the presence of liver metastasis at initial diagnosis predicts poorer outcome in patients with stage IV EGFR-mutant lung adenocarcinoma treated with gefitinib as first-line therapy \[[@pone.0178676.ref026]\]. This result supports the findings of our study, as we demonstrated that among patients with EGFR-mutant disease, those with DLM had worse prognosis than those without DLM. However, the study by Wu et al. focused on EGFR-mutant adenocarcinoma. Our study further demonstrated that in patients with DLM, prognosis of EGFR-mutant group is as poor as wild-type group. The question of why treatment with TKIs was unable to reverse the poor prognosis in EGFR-mutant DLM patients will require further study to resolve. Comparison of OS of patients with single liver metastasis (n = 13), liver plus brain (n = 7), liver plus bone (n = 19), liver plus pleural (n = 5) metastasis, and liver plus more than 1 additional metastatic site (n = 29), as shown in [Fig 4](#pone.0178676.g004){ref-type="fig"}, reveals that there were no differences among the groups. Although the number of patients is small, it can be seen that the presence of liver metastasis leads to poor prognosis, regardless of the presence of other distant metastasis.

![Overall survival of patients with liver plus other distant metastasis.](pone.0178676.g004){#pone.0178676.g004}

Our study has several limitations. First, it was retrospective in nature, and prospective studies are required to verify our findings. Second, the number of NSCLC patients with DLM was small in our study population. Whether a true negative result or inadequate power is the best explanation for the non-inferior outcomes of univariate analysis in NSCLC patients with DLM with or without EGFR mutation will require further investigation. Third, we didn't check ALK gene rearrangement in all patients. Last, under-recognition of liver metastases is possible. As in Robinson's study, the detection rate for lesion less than 1cm is 30--40% \[[@pone.0178676.ref027]\]. In Lardinois' study, integrated positron-emission tomography (PET)-CT would be preferred approach for NSCLC staging \[[@pone.0178676.ref028]\], but in our study we mainly used chest CT, bone scan, brain magnetic resonance imaging for staging. Nevertheless, to the best of our knowledge, this is the first report discussing DLM in the era of TKIs. Maybe in the future, liver metastasectomy could be considered for NSCLC patients with liver metastases in order to improve survival.

Conclusions {#sec010}
===========

DLM was a significant poor prognostic factor in the EGFR-mutant patients treated with EGFR-TKIs, whereas DLM did not affect the prognosis of EGFR-wild-type patients.

Supporting information {#sec011}
======================

###### Patient data.

(XLS)
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Click here for additional data file.
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